

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



The Role of Circulating Biomarkers in the Early Diagnosis of Ovarian Cancer

Ece Gumusoglu and Tuba Gunel

Additional information is available at the end of the chapter

<http://dx.doi.org/10.5772/intechopen.75484>

Abstract

Ovarian cancer is the leading cause of gynecologic-related cancer death and epithelial ovarian cancer (EOC) is the most lethal sub-type. EOC is usually asymptomatic, and few screening tests are available. Diagnosis of ovarian cancer can be difficult because of the nonspecific symptoms. Despite the various diagnostic methods used, there is no reliable early diagnostic test and it needs to be developed. Specific biomarkers may have potential with the least possible invasive procedure. Biomarkers with a high sensitivity to ovarian cancer should be identified. Circulating biomarkers that are significant tools for non-invasive early diagnosis can be analyzed using circulating tumor cells, exosomes, and circulating nucleic acids. Protein, gene, metabolite, and miRNA-based biomarkers can be used for ovarian cancer diagnosis. As non-coding RNAs, MiRNAs may have an important role in ovarian cancer diagnosis due to their effects on mRNA expression levels. The most recent developments regarding the potential of circulating biomarkers to detect early ovarian cancer is presented in this chapter.

Keywords: ovarian cancer, biomarker, cell-free nucleic acids, early diagnosis, miRNA

1. Introduction

Ovarian cancer is a heterogeneous disease and the most important cause of gynecological cancer-induced deaths [1]. It is the fifth most important cause of cancer-related deaths among women in the world [2]. Different types of tumors may develop from each cell type. These tumors are epithelial tumors, germ cell tumors (originating from the ovary cell and follicular), and stromal tumors [3].

Molecular and cellular analyses of these tumor types may lead to earlier diagnosis of ovarian cancer and it is hoped better survival rates. Many factors play a role in the development of cancer, while genomic mutations and epigenetic changes are very important. For this reason, studies on mutations and epigenetic alterations may provide information about features such as early diagnosis, surveillance, and response to treatment.

2. Biomarkers used in the diagnosis of ovarian cancer

Tumor biomarkers are molecules that are produced by cancer cells or cells around them, which can be measured in body fluids or in the blood during the diagnosis, screening or treatment of cancer. Molecules that can be used as tumor biomarkers can be counted as cytoplasmic proteins, enzymes, hormones, surface antigens, receptors, oncofetal antigens (re-emerging proteins in cancer that is normally lost after birth), oncogenes or their products. An ideal tumor biomarker should be sensitive enough for early detection of small tumors while retaining the specificity of the identified cancer type. Unfortunately, however, today there is no known tumor biomarker carrying these features [4].

The features that should be found in an ideal tumor biomarker are given below [5]:

- It should have high specificity; it should be specific to only one type of tumor.
- Must have high sensitivity, should not be detected in cases of physiological or benign tumors.
- Levels should be proportional to tumor characteristics and size.
- The predictive and prognostic benefit of tumor biomarkers should be known.
- Half-life should be short, frequent and serial monitoring is possible.
- It should be cheap and easy to apply.
- Can be used as a screening test.
- Sample taking should be easy.

Potential biomarkers used in ovarian cancer are grouped as gene, protein, metabolite, and miRNA-based biomarkers according to their type [5].

The vast majority of ovarian tumors arise from the accumulation of genetic damage, but the specific genetic pathways that are involved in the development of epithelial, borderline, and malignant tumors are largely unknown. Considering the important relationship between genetic alterations and ovarian tumors, potential ovarian-cancer biomarkers can be found at gene-level (hereditary gene mutations, epigenetic changes, and gene expression) studies. The most common genes associated with epithelial ovarian cancer are shown in **Table 1** [6].

BRCA1, BRCA2, and Lynch syndrome genes show high penetrance and offer lifetime risks of 7–40% for ovarian cancer. Nowadays, the multigene panels used for clinical genetic testing

Gene	Gene full name	Protein class	Score ^a	No. of PMIDs ^b	No. of SNPs ^c
TP53	Tumor protein p53	Transcription factor	0.245958	144	2
CLDN7	Claudin 7	Cell junction protein	0.201099	5	0
ABO	ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase	Transferase	0.200549	3	0
SYNPO2	Synaptopodin 2	Cytoskeletal protein	0.200275	1	0
GPX6	Glutathione peroxidase 6	Oxidoreductase	0.200275	1	0
RSPO1	R-spondin 1		0.200275	1	0
WNT4	Wnt family member 4	Signaling molecule	0.200275	1	0
ATAD5	ATPase family, AAA domain containing 5	Nucleic acid binding	0.200275	1	0
EHMT2	Euchromatic histone lysine methyltransferase 2	Transferase; nucleic acid binding	0.2	1	0
MIR376C	MicroRNA 376c		0.2	1	0
BRCA1	BRCA1, DNA repair associated		0.02933	99	5
ERBB2	erb-b2 receptor tyrosine kinase 2		0.017792	57	0
BRCA2	BRCA2, DNA repair associated	Nucleic acid binding	0.01422	44	4
VEGFA	Vascular endothelial growth factor A	Signaling molecule	0.012847	39	0
MUC16	Mucin 16, cell-surface associated		0.009	25	0
EGFR	Epidermal growth factor receptor		0.008176	22	0
PIK3CA	Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Transferase; kinase	0.007627	20	3
PGR	Progesterone receptor	Transcription factor; receptor; nucleic acid binding	0.007287	10	0
ERCC1	ERCC excision repair 1, endonuclease non- catalytic subunit	Nucleic acid binding	0.007077	18	0
EGF	Epidermal growth factor	Extracellular matrix protein; receptor	0.006528	16	0
ESR1	Estrogen receptor 1	Transcription factor; receptor; nucleic acid binding	0.006528	16	0
IGF2	Insulin like growth factor 2		0.006253	15	1
NBR1	NBR1, autophagy cargo receptor		0.006044	22	0
CDKN1A	Cyclin dependent kinase inhibitor 1A	Enzyme modulator	0.005704	13	0
TNF	Tumor necrosis factor	Signaling molecule	0.005704	13	0
ABCB1	ATP binding cassette subfamily B member 1		0.005495	20	3

Gene	Gene full name	Protein class	Score ^a	No. of PMIDs ^b	No. of SNPs ^c
MLH1	mutL homolog 1	Nucleic acid binding	0.005154	11	0
PTGS2	Prostaglandin-endoperoxide synthase 2	Oxidoreductase	0.005154	11	1
BRAF	B-Raf proto-oncogene, serine/threonine kinase	Transferase; kinase	0.00488	10	1
CDKN2A	Cyclin dependent kinase inhibitor 2A	Enzyme modulator	0.004605	9	0

^aGene-Disease Score.
^bTotal Number of PubMed ID (PMIDs) Supporting the Association.
^cThe Number of Associated Single Nucleotide Polymorphism (SNPs).

Table 1. The most common genes associated with epithelial ovarian cancer.

include the mild-penetrance genes (lifetime risks of 6–13%) such as BRIP1, RAD51C, and RAD51D. The common low-penetrance susceptibility genes make up the rest of the genetic risk. Besides, SNPs have approximately 1% risk which is shown by population-based genome-wide association studies (GWASs) [7]. Expression analyses of quantitative or semi-quantitatively specific genes in serum or tumor tissue can potentially contribute to tumor recognition. In the last decade, analysis of gene expression has gained momentum due to improvements in microarray technology. This is because microarray technology enables analysis of tens or hundreds of gene expressions in a single piece of tissue. Gene expression profiling has focused on three main topics: the separation of tumor tissue by normal ovarian tissue, the identification of different subtypes of ovarian cancer, and the determination of cancer according to possible responses to treatment.

DNA methylation and histone modification are epigenetic mechanisms that play important roles in gene regulation, tumor formation, and progression. Measuring the rate of methylation in specific genes in the promoter region helps early detection of cancer, detection of disease progression, and prediction of therapeutic response. Identification of specific genes that change with epigenetic regulation is one of the areas that are actively studied in ovarian cancer. In this chapter, we want to focus on circulating biomarkers and other types of biomarkers will not be discussed.

3. Tumor materials in circulation: liquid biopsy and their biomarker potentials

Non-invasive tumor diagnosis and screening has become an important area of study. Contrary to tissue biopsy, through detection of circulating tumor cells (CTCs), tumor nucleic acids (“circulating tumor DNA/RNA”), and exosomes, predictive and prognostic markers may potentially be developed which is far less invasive. Hence early and multiple evaluations of the disease can be made, including retrospective follow-up, identification of treatment effects and investigation of clonal development. Isolation and characterization of CTCs, exosomes,

and circulating tumor DNA (ctDNA) will improve cancer diagnosis, treatment, and imaging. Liquid biopsy can be performed “real-time” and at every stage of cancer. Although, it has some potential disadvantages such as; still is not certain to use in cancer diagnosis, difficulties in analysis of data obtaining from high-throughput screening and lack of data verification through clinical trials; it has significant potential for clinical cancer diagnosis in future [8].

3.1. Circulating tumor cells (CTCs)

Some cancer derived cells are detected in peripheral blood, and appear as solid tumor cells that have broken away into the circulation [9]. There are two main types of CTCs to explain this phenomenon. The majority are “Accidental CTCs”, and these are CTCs that are passively pushed by external forces, such as tumor growth, mechanical forces during surgical operation or friction. The rest are CTCs which gain more plasticity and metastatic potential via the epithelial-mesenchymal transition (EMT) process [8]. These CTCs can stay in the non-divided form in the vein, can spread together, or settle into a new tissue to compose the metastatic deposit. Regardless of the CTC pathway, these cells carry important information about tumor composition, metastasis, drug sensitivity, and treatment.

CTCs have been demonstrated to have prognostic value among patients with breast, colorectal, gastric, lung, and pancreatic cancers in previous meta-analyses. However, the value of CTCs in ovarian cancer still remains controversial. Some studies did not observe any correlation between CTC status and prognosis. In contrast, other studies demonstrated an association Zhou et al. has shown that the prognostic value of CTCs was not associated with disease stage but with an elevated CA-125, both of which are known to correlate with prognosis either directly or indirectly. It has also been known that the CTC status was significant in respect to the overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS) in ovarian cancer [10].

CTCs can be detected in both metastatic patients and patients with early, localized tumors. There is a significant potential for CTCs in the clinical management of cancers such as ovarian cancer. CTCs may enable real-time monitoring of treatment efficacy, identification of new therapy targets, and detecting and understanding drug resistance mechanisms [11]. CTC imaging and separation from leukocytes is dependent on reliable cell-surface markers. Based on the precipitation of CTCs in the low-speed centrifuge, the leukocyte fractions can be distinguished via physical features as well. Lee et al. used a nanoroughened microfluidic platform and detected CTCs in the sera of nearly all female participants (53/54, 98.1%) with ovarian cancer [12]. They also showed that although there is no relationship between CTC count and PFS in patients with newly diagnosed epithelial ovarian cancer (EOC), in patients with recurrent disease and chemoresistance; a relationship was found between CTC-cluster positivity and diminished OS [12]. It has been postulated that CTCs could result in metastatic progression and recurrence by way of epithelial-mesenchymal-transition (EMT) or development of stem-like features and hence a reduced OS. Therefore, researchers have tried to identify therapy-resistant tumor cells and to overcome treatment failure by analyzing CTCs transcriptional profiles [13]. In this study, the authors analyzed 15 single CTCs from 3 ovarian cancer patients and found them to be positive for stem cell (CD44, ALDH1A1, Nanog, Oct4) and EMT markers (N-cadherin, vimentin, Snai2, CD117, CD146) [13].

3.2. Circulating cell-free tumor DNA

Chang et al. were the first to examine the amount of cell-free DNA (cfDNA) in a patient's serum as a marker of disease presence in gynecologic malignancies [14, 15]. Cell free tumor DNAs (ctDNAs) circulate in the bloodstream and are derived from tumor cells. The presence of ctDNAs has been proven by detection of tumor-specific anomalies such as the presence of mutation in circulating tumor DNA (ctDNA), loss of heterozygosity of microsatellite, and methylation of CpG islands [16–18]. Similar to CTCs source; ctDNAs are released into the bloodstream in two ways: passively whereby ctDNAs from dead tumor cells and actively whereby ctDNAs are derived from live tumor cells spontaneously [8, 19]. ctDNA and apoptotic cell levels are lower in healthy individuals compared to cancer patients because chronic inflammation and excessive cell death cause accumulation of cell residues. cfDNA (cell-free DNA) is believed to originate from apoptotic cells content and found in elevated levels in cancer patients and related to higher tumor stage [20, 21].

The level of ctDNA is higher in the bloodstream of patients with solid tumors and metastatic disease compared to those without metastases [20, 21]. In patients with metastatic disease, the serum ctDNA level is higher (prevalence 86–100%) when compared to early-staged cancer types and patients with no radiographic evidence of disease (prevalence 49–78%) [20, 22]. Olsen et al. showed that in 86% of patients, ctDNA can be detected approximately 1 year before metastases while they are not observed in those clear of recurrence [23, 24]. The anticipated short half-life of ctDNA of around 2 hours allows for an almost continuous analysis of tumor features including development, metastatic progression, and treatment efficacy. Thus, the identification of ctDNA has extraordinary potential as a potential biomarker for observing tumor load in the patient both prior and during treatment and in follow up [23].

Earlier studies in gynecological malignancies evaluated the presence of ctDNA at one time point using pelvic washings, ascites, serum, and plasma. Pereira et al. has demonstrated that serial estimation of ctDNA is a surveillance biomarker in gynecologic malignancies that is as sensitive and specific as the FDA-approved serum biomarker CA-125 [25]. Additionally, disease recurrence can be detected months earlier with ctDNA than CT checking [25]. Furthermore, the survival profiles of patients can be predicted with ctDNA level during the start of primary treatment, debulking surgery, and combined platinum/taxane doublet chemotherapy [25]. Both improved progression free and overall survival appear to be associated with undetectable levels of ctDNA [25]. Additionally, ctDNA level maybe a stronger predictor than CA-125 of tumor size because of the longer half-life of CA-125 (9–44 days). It is also shown that in some patients, relapse of disease can be detected with ctDNA approximately 7 months before any CT scan changes [25]. Pereira et al. detected occult ovarian cancer cases by continuously monitoring the ctDNA even during apparent clinical remission [25]. These studies demonstrate that ctDNA could be used in early detection, it can act as a marker of disease stage as well as disease progression for gynecological cancers especially ovarian cancer.

Early diagnosis seems to be the best solution to reduce rates of ovarian cancer deaths unless highly effective drugs are developed with fewer side effects. Bettgowda et al. showed that for ctDNA detection in solid tumors, patients are treated at an earlier stage resulting in improved

survival [21]. Moreover, even in stage I patients (usually curable with surgery alone), detection of ctDNA level can be observed in around 47% of all patients [21]. Using ctDNA-level analysis, ovarian cancer can be detected in around 70% of all stage III patients [21].

3.3. Circulating cell-free tumor RNA (ctRNA)

Cancer cells have a very specific gene expression profile which differs from normal tissues. These tumor-specific gene transcripts can be detected in the circulation of cancer patients [26]. Despite the high amount of RNase present in the blood, circulating RNAs have been found to be surprisingly stable. This can be explained by the possibility that RNA is destructively protected by exosomes (such as microparticles, microvesicles, multivesiculas) that pass through the cell membrane into the bloodstream [26]. In addition, these mRNAs that are present in blood can be used as prognostic and predictive biomarkers [27]. Similar to ctDNA, ctRNA requires further study to assess the exact value as a biomarker in ovarian cancer.

3.3.1. Circulating microRNAs

MicroRNAs (miRNAs) are RNAs that do not encode proteins, at about 22 nucleotides in length, but they are involved with translation suppression, mRNA degradation, or sequencing specific gene regulation. Thus these molecules regulate various biological processes such as development, cell proliferation, differentiation, and apoptosis [28]. Approximately 3% of human genes encode miRNAs, while about 30% of genes encoding protein are regulated by miRNAs. These miRNAs vary according to the type of each cell, the stage of development, and differentiation of the cell. The release and biological functions of extracellular miRNAs are still not fully understood [29].

It has been shown that blood miRNAs in cancer patients have the similar importance as the miRNAs in tissues, and the relationship between solid tumors and miRNA expression profiles in the blood have been investigated [30, 31]. Circulating miRNAs are not bonded to the cell but are protected against endogenous RNase breakdown by binding to microvesicles, exosomes, microparticles, apoptotic bodies, and protein-miRNA complexes [32]. MiRNAs are resistant to severe conditions such as high temperature, low/high pH, long-term storage, and over-applied freezing/thawing [29]. Measurement of circulating miRNA level is difficult because it can be contaminated with cellular miRNAs of different hematopoietic origin [29]. The isolation and stabilization protocols of circulating miRNAs should be standardized and the cancer patient's plasma should be selectively distinguishable at the single molecule level [33]. MiRNA expression varies in tumor tissue with respect to normal tissue, and these changes can be detected in serum/plasma samples of cancer patients when compared to healthy individuals [34]. Further work is needed because of the low level of difference detected [29]; however miRNA has been shown to play an important role in cancer development as a new oncogene or tumor-suppressor gene class that varies according to the target gene [35].

In eukaryotic cells, there are several stages in miRNA biogenesis stages (transcription, pre-miRNA clipping, pre-miRNA transport, and pre-miRNA cloning) [36, 37]. MiRNA expression

levels vary from normal to ovarian cancer, with epigenetic changes, genetic changes (such as copy number changes), or differentiated expression of transcriptional factors, targeting miRNA genes. Transcriptional gene silencing in cancer cells is often associated with epigenetic defects [38, 39]. Studies have suggested that dysfunction or irregularity may occur in key proteins that are effective in miRNA biogenesis and may lead to tumor formation [39].

In recent years, many studies have been performed on the miRNA expression profile in EOC and it has been shown that there are significant differences in the miRNA expression profile compared to normal [35]. Iorio et al. compared 59 EOC operation samples with 15 normal ovarian species using a “custom” microarray and found 29 differently expressed miRNAs [35]. In EOC patients, miRNA expression profiles obtained from circulating tumor exosomes were compared with benign tumors and normal individuals and separated by different expression profiles. In this study, exosomes were separated by magnetic beads and anti-EPCAM antibodies, and miRNAs were analyzed by isolated microarray. As a result, there are several differentially expressed miRNAs in ovarian cancer samples [40]. In a study by Resnick et al., real-time PCR analysis of miRNA expression was performed on the serum collected from ovarian cancer patients and normal subjects, with different miRNAs expression found [41]. Patients with the three up-regulated miRNAs (miR-21, miR-92, and miR-93) were found to have a normal level of CA-125. Therefore, miRNA analysis may be complementary to other diagnostic methods [41].

It is clear that miRNAs play a crucial role in both normal and pathological processes due to their ability to regulate the expression of specific genes. However, no consensus has been reached as to the exact role/potential in diagnosis, metastasis, and prediction of response to treatment in EOC [28]. In addition, ovarian cancer is a heterogeneous disease, treatment and diagnostic options may vary from individual to individual; in this context, the tissue and origin specificity of miRNAs may be exploited and individualized treatment methods may be applied [42].

3.3.2. Circulating long non-coding RNAs

The Long Non-Coding RNAs (lncRNAs) are defined as >200 nucleotides in length and divided into five subclasses, which are intergenic, intronic, sense overlapping, *anti*-sense, and bidirectional lncRNAs [43]. lncRNAs are involved in various regulation processes which include protein-coding genes, functions at the level of splicing, chromatin remodeling, transcriptional control, and post-transcriptional processing after binding to DNA, RNA, or proteins [44]. These differ from tissue to tissue [45, 46] and lncRNAs play a role in growth, metabolism, and cancer metastasis [20, 47]. In several human cancer types, differentially expressed lncRNAs have been identified [48] which can be related to cancer metastasis and prognosis [49–51]. In addition, lncRNAs are specific for certain tumor origins such as the lymphatics, the cardiovascular or nervous system, circulating peripheral blood cells, or hematologic stem cells. Therefore, circulating lncRNAs may be informative about the tumor microenvironment [20, 52].

In ovarian cancer, lncRNAs have been shown to regulate several cancer processes such as development, metastasis, and relapse. Gao et al. [53] showed that a lncRNA named *HIST1*

(human ovarian cancer-specific transcript 1) plays a role in key biological pathways of EOC through the stimulation of tumor cell migration, invasion, and proliferation by inhibiting let-7b which is one of the most important miRNA involved in EOC [54]. In another study, Tong et al. showed that a lncRNA named RP11-190D6.2 regulates the WW domain-containing oxidoreductase (WWOX) expression by acting like an antisense transcript of this gene [55]. WWOX is linked with poor prognosis in several cancers, including EOC [56]. In addition, RP11-190D6.2 appears to play a role in the regulation of tumor metastasis, thus it can be counted as a potential biomarker and therapeutic target for EOC [55]. Zhou et al. compared several lncRNA expression profiles in a large number of OvCa patients from TCGA and found an eight-lncRNA signature predictive of overall survival [57]. Moreover, using lncRNA expression profiles, they could separate similarly aged patient into high-risk and low-risk groups, identify good or poor survival potential of patients, the eight-lncRNA signature maintained independent prognostic value, and was significantly correlated with the response to chemotherapy [57]. In a separate study [51], examining the expression profiles of lncRNAs and mRNAs in the high-throughput molecular profiles of OV patients; they found a correlation between lncRNA and malignant OV progression. Therefore; they suggest that two specific lncRNAs (RP11-284 N8.3.1 and AC104699.1.1) as may be candidate biomarkers for prognosis [51]. Clearly further study is required to understand their clinical application as a biomarker in EOC.

3.3.3. Circulating Piwi RNAs(piRNA)

Piwi RNAs (PiRNAs) are single-stranded, 26–31 nucleotide long RNAs which may inhibit transposons and target mRNAs through the formation of the miRNA silencer complex (RISC). Post-transcriptional regulation of piRNA (piRISC) happens in the cytoplasm [58]. The piRISC protects the integrity of the genome from alterations made by transposable elements (TE)—by silencing them; mRNA and lncRNA are other targets of piRNA complexes [58, 59]. piRNAs pathways play an important role to regulate some cancer-related pathways such as DNA hypomethylation and transposable element (TE) derepression. *L1* is a piRNA pathway gene that regulates these pathways, also overexpression of these genes (*PIWIL1* and *2*), have been shown in several tumor tissues [60]. Lim et al. showed that overexpression piRNA pathway genes and *L1* elements may have a role in EOC [60]. They compared the EOC tissues and cell lines to benign and normal ovaries and found overexpression of *PIWIL1* and *MAEL*, known as a cancer/testis gene [61] which are two genes of piRNA pathway which is a germ-line-specific RNA silencing mechanism. In situ analysis indicated that *L1*, *PIWIL1*, *PIWIL2*, and *MAEL* are up-regulated in cancerous cells, while *MAEL* and *PIWIL2* genes are expressed in the stromal cells lining tumor tissues as well. *PIWI*, *MAEL* genes are essential for *Drosophila* and other vertebrates' germ-line stem-cell differentiation [60, 62]. These gene changes may promote a change in cell composition or identity in the tissue surrounding the cancer cells [60]. Also cancer stem cells may have potential as a biomarker for stem-cell definition [60, 63].

In addition, synthetic piRNAs may offer a new therapeutic approach through their use in silencing the expression of cancer-related genes. This approach has an advantage over other miRNA-based blocking methods because it does not require extra components for processing such as Dicer [59].

3.4. Exosomes and circulating microvesicles

Exosomes are multivesicular endosomal-derived extracellular vesicles (EVs) which are 30–120 nm size [64–67]. Exosomes can be distinguished from microvesicles which are heterogeneous in size (50–1500 nm) and result from the plasma membrane directly via a budding mechanism [68, 69]. Exosomes include several molecules such as proteins, metabolites, RNAs (mRNA, miRNA, long non-coding RNA), DNAs (mtDNA, ssDNA, dsDNA), and lipids and are used in cell communication [64, 70, 71]. Similar to circulating microvesicles, exosomes have also been shown to have specific functions and play an important role in coagulation, intercellular signaling, and the management of debris. Both circulating parts of the cell are found in different body and interstitial fluids [72, 73].

Tumor-derived exosomes are different from circulating healthy exosomes in terms of number of exosomes, content, and also cell-surface proteins [74]. Exosomes can be detected and isolated with several markers especially cell-surface proteins including those found only in the primary tissue. TGF β 1, MAGE 3/6 proteins have a cell-surface biomarker feature special for ovarian cancer. These markers can be detected by filtration and ultracentrifugation methods in ovarian cancer plasma samples and can be used for prognosis/therapy monitoring of disease [74, 77]. Exosome contents are variable for cancer types as well. Taylor et al. indicated that several ovarian cancer specific exosomal miRNAs, (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205, miR-214), have been differentiated in serum samples by magnetic-activated cell-sorting (MACs) using anti-EpCAM array for diagnosis and screening of stage [40]. Exosomes are informative about tumor-specific features such as metastatic or benign form, stage, response to chemotherapies, and other drugs at that point in time via a possible blood sample [64].

Microvesicles have several common features with the primary cell such as membrane lipids, receptors, and diverse types of nucleic acids and proteins [75]. As in exosomes, microvesicles also have a potential to be biomarkers in several malignancies. Galindo-Hernandez et al. demonstrated that there were an increased number of microvesicles in breast cancer serum compared to healthy control samples [76]. It is also revealed that microvesicles derived from renal cancer stem cells include different miRNAs and mRNAs and these appear to play a function in tumor vascularization [75, 77, 78]. Microvesicles originated from tumor cells have been found in biological fluids in ovarian cancer. It has been shown that the number of microvesicles in malignant ovarian tumors is higher when compared to benign and nonmalignant pathologies (e.g., ovarian serous cysts, mucinous cystadenomas, and fibromas) [79]. Ovarian cancer-induced ascites contains high levels of proteolytic enzymes such as matrix metalloproteinase (MMP-2, MMP-9) and urokinase-type plasminogen activator (uPA), which are the enzymes carried inside microvesicles [80–82]. Microvesicles may represent an ideal biomarker for ovarian cancer diagnosis and prognosis.

4. Biomarker detection technologies for ovarian cancer

High-throughput techniques of cellular transcriptome analysis mean that gene expression can be correlated with various aspects of disease in a variety of cancer types. This technology

used today in ovarian cancer research, such as expression microarrays and CGH, Real-time PCR, and Next-Generation Sequencing (NGS) allow genome-wide scanning and the discovery of altered genes involved in cancer.

4.1. Real-time PCR

Cell-free nucleic acids reflect both normal and tumor-derived nucleic acids released into the circulation through cellular necrosis and apoptosis. Stroun et al. have demonstrated with Reverse Transcription Quantitative PCR (RT-qPCR) that there is a consistent correlation between tumor load and quantity of cell-free DNA detected in a wide range of malignancies including ovarian cancer [83]. Several studies in OC with free DNA have also shown that miRNAs are abnormally expressed. Initial studies identifying tumor-derived miRNAs in the circulation of OC patients was published by Taylor et al. [40]. Zou et al. identified nine differentially expressed microRNAs (microRNA199a-5p, microRNA199a-3p, microRNA199b3p, microRNA-645, microRNA-335, microRNA-18b, and microRNA-141) through qRT-PCR expression analysis in SKOV3/DDP and A2780/DDP cells and these agreed with microRNA chip results [84].

4.2. Microarray

Microarrays together with clustering analysis have allowed genome-wide expression patterns in a lot of cancer types to be deciphered and compared. Wong et al. studied a group of genes (CLDN7, EPHA1, FOXM1, and FGF7), for the validation of the microarray findings; these were selected as these genes were associated with the alteration of crucial pathways involved in the regulation of cell cycle and cell proliferation [85]. Liu et al. [86] using the bioinformatics analyses of mRNA expression profiles retrieved from the Oncomine and Gene Expression Omnibus (GEO) Profiles online databases, they enriched two biological processes (cell cycle and microtubule-related) and identified six genes (ALDH1A2, ADH1B, NELL2, HBB, ABCA8, and HBA1) that all were associated with ovarian cancer progression.

4.3. Next-generation sequencing

Clinical cancer next-generation sequencing (NGS) assays are dependent on many software subsystems and databases to deliver their results. The building of software systems for clinical use is a mandatory requirement of reliability and reproducibility imposed by diagnostic laboratory accreditation bodies such as Clinical Laboratory Improvement Amendments (CLIA), National Association of Testing Authorities (NATA), and the International Organization for Standardization (ISO 15189).

Pinto et al. [87] validated the use of next-generation sequencing (NGS) for the detection of BRCA1/BRCA2 point mutations in a diagnostic setting and also investigated the role of other genes associated with hereditary breast and ovarian cancer in Portuguese families. They obtained 100% sensitivity and specificity (total of 506 variants) for the detection of BRCA1/BRCA2 point mutations with their bioinformatics pipeline using a targeted enrichment approach when compared to the gold standard Sanger sequencing.

5. Conclusion

Ovarian cancer is one of the most significant and fatal gynecological cancer types worldwide. The earlier this disease can be detected, the better the success of treating it. There are several detection methods for ovarian cancer, but molecular diagnosis methods are more accurate, faster, and suitable for early detection. Recent developments have focused on identifying biological material with newer technological devices and these have become more precise, reliable, and more widely available over a short period of time. Although molecular markers, which are specific for ovarian cancer, have been extensively studied, they are still not used in a clinical setting. Clearly a greater understanding of their mechanisms and specificities are needed before they can be applied to early detection of OC.

Liquid biopsy using body fluids (e.g. blood, urine, saliva, and ascites) to isolate and characterize CTCs, exosomes, circulating tumor DNA, RNAs, and circulating free small RNAs is a new technique used in the detection and treatment of several diseases. Clearly further investigation is required but it is hoped that this may become a very important tool for early detection of ovarian cancer. In addition, these biomarkers may become an important part of the clinical strategies used in cancer diagnosis, treatment, and imaging. In this chapter, their roles in the early detection and management of ovarian cancer have been discussed. It is hoped that as our understanding of these markers increases, we will see an improvement in the rate of early cancer detection and ultimately increased survival.

Author details

Ece Gumusoglu^{1*} and Tuba Gunel^{1,2}

*Address all correspondence to: ece.gumusoglu@istanbul.edu.tr

1 Faculty of Science, Molecular Biology and Genetics, Istanbul University, Istanbul, Turkey

2 Center for Research and Practice in Bio-technology and Genetic Engineering, Istanbul, Turkey

References

- [1] Chu CS, Rubin SC. Screening for ovarian cancer in the general population. Best Practice & Research. Clinical Obstetrics & Gynaecology. 2006;**20**(2):307-320
- [2] Allain DC. Genetic counseling and testing for common hereditary breast cancer syndromes: A paper from the 2007 William Beaumont hospital symposium on molecular pathology. The Journal of Molecular Diagnostics. 2008;**10**(5):383-395
- [3] Berek JS, Crum C, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum. International Journal of Gynaecology and Obstetrics. 2015;**131**(Suppl 2):S111-S122

- [4] Burtis CA, Ashwood E, Bruns DE, Sawyer BG. Tietz Fundamentals of Clinical Chemistry; 2008
- [5] Sharma S. Tumor markers in clinical practice: General principles and guidelines. Indian Journal of Medical and Paediatric Oncology. 2009;**30**(1):1-8
- [6] Zhang S, Lin H, Kong S, Wang S, Wang H, Wang H, et al. Physiological and molecular determinants of embryo implantation. Molecular Aspects of Medicine. 2013;**34**(5):939-980
- [7] Rahman B, Side L, Gibbon S, Meisel SF, Fraser L, Gessler S, et al. Moving towards population-based genetic risk prediction for ovarian cancer. BJOG: An International Journal of Obstetrics and Gynaecology. 2017;**124**(6):855-858
- [8] Zhang W, Xia W, Lv Z, Ni C, Xin Y, Yang L. Liquid biopsy for cancer: Circulating tumor cells, circulating free DNA or exosomes? Cellular Physiology and Biochemistry. 2017;**41**(2):755-768
- [9] Joosse SA, Pantel K. Biologic challenges in the detection of circulating tumor cells. Cancer Research. 2013;**73**(1):8-11
- [10] Zhou Y, Bian B, Yuan X, Xie G, Ma Y, Shen L. Prognostic value of circulating tumor cells in ovarian cancer: A meta-analysis. PLoS One. 2015;**10**(6):e0130873
- [11] Kolostova K, Pinkas M, Cegan M, Matkowski R, Jakabova A, Pospisilova E, Svobodova P, Spicka J, Bobek V. Molecular characterization of circulating tumor cells in ovarian cancer. American Journal of Cancer Research. 2016;**6**(5):973-980
- [12] Lee M, Kim EJ, Cho Y, Kim S, Chung HH, Park NH, et al. Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer. Gynecologic Oncology. 2017;**145**(2):361-365
- [13] Blassl C, Kuhlmann JD, Webers A, Wimberger P, Fehm T, Neubauer H. Single cell gene expression analysis of circulating tumor cells in ovarian cancer reveals CTCs co-expressing stem cell and mesenchymal markers. Geburtshilfe und Frauenheilkunde. 2016;**76**(10):P005
- [14] Chang H-W, Lee SM, Goodman SN, Singer G, Cho SKR, Sokoll LJ, et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. JNCI: Journal of the National Cancer Institute. 2002;**94**(22):1697-1703
- [15] Kamat AA, Sood AK, Dang D, Gershenson DM, Simpson JL, Bischoff FZ. Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR. Annals of the New York Academy of Sciences. 2006;**1075**(1):230-234
- [16] Silva JM, Dominguez G, Villanueva MJ, Gonzalez R, Garcia JM, Corbacho C, et al. Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients. British Journal of Cancer. 1999;**80**:1262
- [17] Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Research. 1999;**59**(1):67-70

- [18] Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterations in serum DNA of head and neck cancer patients. *Nature Medicine*. 1996;**2**(9):1035-1037
- [19] Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: Monitoring cancer-genetics in the blood. *Nature Reviews Clinical Oncology*. 2013;**10**:472
- [20] Rapisuwon S, Vietsch EE, Wellstein A. Circulating biomarkers to monitor cancer progression and treatment. *Computational and Structural Biotechnology Journal*. 2016;**14**:211-222
- [21] Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Science Translational Medicine*. 2014;**6**(224):224ra24
- [22] Speicher MR, Pantel K. Tumor signatures in the blood. *Nature Biotechnology*. 2014;**32**(5):441-443
- [23] Harris FR, Kovtun IV, Smadbeck J, Multinu F, Jatoi A, Kosari F, et al. Quantification of somatic chromosomal rearrangements in circulating cell-free DNA from ovarian cancers. *Scientific Reports*. 2016;**6**:29831
- [24] Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. *EMBO Molecular Medicine*. 2015;**7**(8):1034-1047
- [25] Pereira E, Camacho-Vanegas O, Anand S, Sebra R, Catalina Camacho S, Garnar-Wortzel L, et al. Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers. *PLoS One*. 2015;**10**(12):e0145754
- [26] Zhou J, Shi YH, Fan J. Circulating cell-free nucleic acids: Promising biomarkers of hepatocellular carcinoma. *Seminars in Oncology*. 2012;**39**(4):440-448
- [27] Pucciarelli S, Rampazzo E, Briarava M, Maretto I, Agostini M, Digito M, et al. Telomere-specific reverse transcriptase (hTERT) and cell-free RNA in plasma as predictors of pathologic tumor response in rectal cancer patients receiving neoadjuvant chemoradiotherapy. *Annals of Surgical Oncology*. 2012;**19**(9):3089-3096
- [28] Zhang B, Cai FF, Zhong XY. An overview of biomarkers for the ovarian cancer diagnosis. *European Journal of Obstetrics, Gynecology, and Reproductive Biology*. 2011;**158**(2):119-123
- [29] Gold B, Cankovic M, Furtado LV, Meier F, Gocke CD. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? *The Journal of Molecular Diagnostics*. 2015;**17**(3):209-224
- [30] van Schooneveld E, Wouters MC, Van der Auwera I, Peeters DJ, Wildiers H, Van Dam PA, et al. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. *Breast Cancer Research*. 2012;**14**(1):R34

- [31] Mitchell PS, Parkin RK, Kroh EM, Frits BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. *Proceedings of the National Academy of Sciences of the United States of America*. 2008;105
- [32] Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. *Nature Cell Biology*. 2011;13(4):423-433
- [33] Hastings ML, Palma J, Duelli DM. Sensitive PCR-based quantitation of cell-free circulating microRNAs. *Methods*. 2012;58(2):144-150
- [34] Godfrey AC, Xu Z, Weinberg CR, Getts RC, Wade PA, LA DR, et al. Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort. *Breast Cancer Research : BCR*. 2013;15(3):R42-R4R
- [35] Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. *Cancer Research*. 2007;67(18):8699-8707
- [36] Lee YS, Dutta A. MicroRNAs in cancer. *Annual Review of Pathology*. 2009;4:199-227
- [37] Ozsolak F, Poling LL, Wang Z, Liu H, Liu XS, Roeder RG, et al. Chromatin structure analyses identify miRNA promoters. *Genes & Development*. 2008;22(22):3172-3183
- [38] Soto-Reyes E, González-Barrios R, Cisneros-Soberanis F, Herrera-Goepfert R, Pérez V, Cantú D, et al. Disruption of CTCF at the miR-125b1 locus in gynecological cancers. *BMC Cancer*. 2012;12(1):40
- [39] Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. *Proceedings of the National Academy of Sciences*. 2008;105(19):7004-7009
- [40] Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. *Gynecologic Oncology*. 2008;110(1):13-21
- [41] Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. *Gynecologic Oncology*. 2009;112(1):55-59
- [42] Hausler SF, Keller A, Chandran PA, Ziegler K, Zipp K, Heuer S, et al. Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. *British Journal of Cancer*. 2010;103(5):693-700
- [43] Archer K, Broskova Z, Bayoumi AS, Teoh JP, Davila A, Tang Y, et al. Long non-coding RNAs as master regulators in cardiovascular diseases. *International Journal of Molecular Sciences*. 2015;16(10):23651-23667
- [44] Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: Insights into functions. *Nature Reviews Genetics*. 2009;10:155
- [45] Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, et al. GENCODE: The reference human genome annotation for the ENCODE project. *Genome Research*. 2012;22(9):1760-1774

- [46] Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression. *Genome Research*. 2012;**22**(9):1775-1789
- [47] Silva A, Bullock M, Calin G. The clinical relevance of long non-coding RNAs in cancer. *Cancers (Basel)*. 2015;**7**(4):2169-2182
- [48] Yang TY. A simple rank product approach for analyzing two classes. *Bioinformatics and Biology Insights*. 2015;**9**:119-123
- [49] Han L, Zhang EB, Yin DD, Kong R, Xu TP, Chen WM, et al. Low expression of long noncoding RNA PANDAR predicts a poor prognosis of non-small cell lung cancer and affects cell apoptosis by regulating Bcl-2. *Cell Death & Disease*. 2015;**6**:e1665
- [50] Liz J, Esteller M. lncRNAs and microRNAs with a role in cancer development. *Biochimica et Biophysica Acta*. 2016;**1859**(1):169-176
- [51] Guo Q, Cheng Y, Liang T, He Y, Ren C, Sun L, et al. Comprehensive analysis of lncRNA-mRNA co-expression patterns identifies immune-associated lncRNA biomarkers in ovarian cancer malignant progression. *Scientific Reports*. 2015;**5**:17683
- [52] Arita T, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Shoda K, et al. Circulating long non-coding RNAs in plasma of patients with gastric cancer. *Anticancer Research*. 2013;**33**(8):3185-3193
- [53] Gao Y, Meng H, Liu S, Hu J, Zhang Y, Jiao T, et al. lncRNA-HOST2 regulates cell biological behaviors in epithelial ovarian cancer through a mechanism involving microRNA let-7b. *Human Molecular Genetics*. 2015;**24**(3):841-852
- [54] Yun J, Frankenberger CA, Kuo WL, Boelens MC, Eves EM, Cheng N, et al. Signalling pathway for RKIP and Let-7 regulates and predicts metastatic breast cancer. *The EMBO Journal*. 2011;**30**(21):4500-4514
- [55] Tong W, Yang L, Yu Q, Yao J, He A. A new tumor suppressor lncRNA RP11-190D6.2 inhibits the proliferation, migration, and invasion of epithelial ovarian cancer cells. *Onco Targets and Therapy*. 2017;**10**:1227-1235
- [56] Yan H, Tong J, Lin X, Han Q, Huang H. Effect of the WWOX gene on the regulation of the cell cycle and apoptosis in human ovarian cancer stem cells. *Molecular Medicine Reports*. 2015;**12**(2):1783-1788
- [57] Zhou M, Sun Y, Sun Y, Xu W, Zhang Z, Zhao H, et al. Comprehensive analysis of lncRNA expression profiles reveals a novel lncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer. *Oncotarget*. 2016;**7**(22):32433-32448
- [58] Siomi MC, Sato K, Pezic D, Aravin AA. PIWI-interacting small RNAs: The vanguard of genome defence. *Nature Reviews Molecular Cell Biology*. 2011;**12**:246
- [59] Assumpção CB, Calcagno DQ, Araújo TMT, Batista dos Santos SE, Ribeiro dos Santos ÂKC, Riggins GJ, et al. The role of piRNA and its potential clinical implications in cancer. *Epigenomics*. 2015;**7**(6):975-984

- [60] Lim SL, Ricciardelli C, Oehler MK, Tan IM, Russell D, Grutzner F. Overexpression of piRNA pathway genes in epithelial ovarian cancer. *PLoS One*. 2014;**9**(6):e99687
- [61] Xiao L, Wang Y, Zhou Y, Sun Y, Sun W, Wang L, et al. Identification of a novel human cancer/testis gene MAEL that is regulated by DNA methylation. *Molecular Biology Reports*. 2010;**37**(5):2355-2360
- [62] Pek JW, Lim AK, Kai T. *Drosophila maelstrom* ensures proper germline stem cell lineage differentiation by repressing microRNA-7. *Developmental Cell*. 2009;**17**(3):417-424
- [63] Foster R, Buckanovich RJ, Rueda BR. Ovarian cancer stem cells: Working towards the root of stemness. *Cancer Letters*. 2013;**338**(1):147-157
- [64] Soung YH, Ford S, Zhang V, Chung J. Exosomes in cancer diagnostics. *Cancers (Basel)*. 2017;**9**(1):1-11
- [65] Tkach M, Thery C. Communication by extracellular vesicles: Where we are and where we need to go. *Cell*. 2016;**164**(6):1226-1232
- [66] Théry C, Zitvogel L, Amigorena S. Exosomes: Composition, biogenesis and function. *Nature Reviews Immunology*. 2002;**2**:569
- [67] Keller S, Sanderson MP, Stoeck A, Altevogt P. Exosomes: From biogenesis and secretion to biological function. *Immunology Letters*. 2006;**107**(2):102-108
- [68] Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. *Annual Review of Cell and Developmental Biology*. 2014;**30**:255-289
- [69] Raposo G, Stoorvogel W. Extracellular vesicles: Exosomes, microvesicles, and friends. *The Journal of Cell Biology*. 2013;**200**(4):373-383
- [70] El Andaloussi S, Mäger I, Breakefield XO, Wood MJA. Extracellular vesicles: Biology and emerging therapeutic opportunities. *Nature Reviews Drug Discovery*. 2013;**12**:347
- [71] De Toro J, Herschlik L, Waldner C, Mongini C. Emerging roles of exosomes in normal and pathological conditions: New insights for diagnosis and therapeutic applications. *Frontiers in Immunology*. 2015;**6**:203
- [72] Muralidharan-Chari V, Clancy JW, Sedgwick A, D'Souza-Schorey C. Microvesicles: Mediators of extracellular communication during cancer progression. *Journal of Cell Science*. 2010;**123**(10):1603-1611
- [73] Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. *Kidney International*. 2010;**78**(9):838-848
- [74] Szajnik M, Derbis M, Lach M, Patalas P, Michalak M, Drzewiecka H, et al. Exosomes in plasma of patients with ovarian carcinoma: Potential biomarkers of tumor progression and response to therapy. *Gynecology & Obstetrics (Sunnyvale)*. 2013;(Suppl 4):3
- [75] Verma M, Lam TK, Hebert E, Divi RL. Extracellular vesicles: Potential applications in cancer diagnosis, prognosis, and epidemiology. *BMC Clinical Pathology*. 2015;**15**:6

- [76] Galindo-Hernandez O, Villegas-Comonfort S, Candanedo F, Gonzalez-Vazquez MC, Chavez-Ocana S, Jimenez-Villanueva X, et al. Elevated concentration of microvesicles isolated from peripheral blood in breast cancer patients. *Archives of Medical Research*. 2013;**44**(3):208-214
- [77] Atala A. Re: Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. *The Journal of Urology*. 2012; **187**(4):1506-1507
- [78] Grange C, Tapparo M, Collino F, Vitillo L, Damasco C, Deregibus MC, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. *Cancer Research*. 2011;**71**(15):5346-5356
- [79] Ginestra A, Miceli D, Dolo V, Romano FM, Vittorelli ML. Membrane vesicles in ovarian cancer fluids: A new potential marker. *Anticancer Research*. 1999;**19**(4C):3439-3445
- [80] Young TN, Rodriguez GC, Rinehart AR, Bast JRC, Pizzo SV, Stack MS. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: Purification of matrix metalloproteinase 2. *Gynecologic Oncology*. 1996;**62**(1):89-99
- [81] Dolo V, D'Ascenzo S, Violini S, Pompucci L, Festuccia C, Ginestra A, Vittorelli ML, Canevari S, Pavan A. Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells *in vivo* and *in vitro*. *Clinical & Experimental Metastasis*. 1999;**17**: 131-140
- [82] Graves LE, Ariztia EV, Navari JR, Matzel HJ, Stack MS, Fishman DA. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. *Cancer Research*. 2004; **64**(19):7045-7049
- [83] Stroun M, Maurice P, Vasioukhin V, Lyautey J, Lederrey C, Lefort F, et al. The origin and mechanism of circulating DNA. *Annals of the New York Academy of Sciences*. 2000;**906**(1):161-168
- [84] Zou J, Yin F, Wang Q, Zhang W, Li L. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer. *International Journal of Clinical and Experimental Pathology*. 2015;**8**(6):6847-6858
- [85] Wong YL, Dali AZ, Mohamed Rose I, Jamal R, Mokhtar NM. Potential molecular signatures in epithelial ovarian cancer by genome wide expression profiling. *Asia-Pacific Journal of Clinical Oncology*. 2016;**12**(2):e259-e268
- [86] Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of rho-associated kinase signaling prevents breast cancer metastasis to human bone. *Cancer Research*. 2009;**69**(22): 8742-8751
- [87] Pinto P, Paulo P, Santos C, Rocha P, Pinto C, Veiga I, et al. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity. *Breast Cancer Research and Treatment*. 2016;**159**(2): 245-256